Radiopharmaceutical developer Mallinckrodt Medical said that itwill begin sales in Sweden of TechneScan Q12, a technetium-basedcardiac imaging agent, following approval of the agent by Sweden'shealth authorities. Sweden is the first country in the
Radiopharmaceutical developer Mallinckrodt Medical said that it
will begin sales in Sweden of TechneScan Q12, a technetium-based
cardiac imaging agent, following approval of the agent by Sweden's
health authorities. Sweden is the first country in the European
Union to approve TechneScan, and certifications in other European
nations are expected. St. Louis-based Mallinckrodt filed a new
drug application for the product in the U.S. in 1994.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.